Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$13.10

0.22 (1.71%)

07:32
10/15/18
10/15
07:32
10/15/18
07:32

Arrowhead files for regulatory clearance to begin Phase 1 study of ARO-ANG3

Arrowhead Pharmaceuticals announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias and metabolic diseases. ARO-ANG3 will be the fourth therapeutic candidate to enter clinical studies that leverages Arrowhead's Targeted RNAi Molecule platform. Pending approval, Arrowhead intends to proceed with AROANG1001, a Phase 1 single and multiple dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of ARO-ANG3 in adult healthy volunteers and dyslipidemic patients. The study is designed to enroll up to 70 subjects. An application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration. As a reminder, Arrowhead will host a Research & Development Day to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics that leverage the Company's proprietary Targeted RNAi Molecule platform on October 16, 2018 in New York City.

  • 09

    Nov

ARWR Arrowhead
$13.10

0.22 (1.71%)

10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
10/04/18
CANT
10/04/18
NO CHANGE
Target $24
CANT
Overweight
Arrowhead price target raised to $24 from $18 at Cantor Fitzgerald
Cantor Fitzgerald analyst Justin Kim raised his price target for Arrowhead (ARWR) to $24 from $18 following a newly announced collaboration and license agreement with Johnson & Johnson's (JNJ) subsidiary Janssen. Overall, the analyst feels the agreement is positive for the company as the support of a large partner could speed up the development timelines, increase market penetration with expertise, and validates the TRiM platform that Arrowhead uses. The additional cash will support Arrowhead's internal clinical development, he adds. Kim reiterates an Overweight rating on Arrowhead's shares.
10/04/18
PIPR
10/04/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead price target raised to $25 from $17 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead (ARWR) to $25 from $17 after the company signed a license and collaboration agreement with Johnson & Johnson's (JNJ) Janssen Pharmaceuticals to develop and commercialize ARO-HBV and up to 3 new TRiM candidates. The analyst notes that Arrowhead will receive $175M cash up front, a $75M equity investment, up to $3.5B in milestones plus up to mid-teens royalties on ARO-HBV. Tenthoff views this deal as transformative for Arrowhead, dramatically strengthening the balance sheet and finding a strong partner for ARO-HBV, while retaining the rest of TRiM pipeline. He reiterates an Overweight rating on Arrowhead's shares.
09/14/18
JEFF
09/14/18
NO CHANGE
Target $24
JEFF
Buy
Arrowhead price target raised to $24 from $20 at Jefferies
Jefferies analyst Maury Raycroft raised his price target for Arrowhead Pharmaceuticals to $24 after the company last week reported initial ARO-HBV data at the World Gastroenterologists Summit. The update was unexpected and an early glimpse into what should be a more mature, robust dataset at the American Association for the Study of Liver Diseases meeting, Raycroft tells investors in a research note. He sees the de-risking as a positive and keeps a Buy rating on Arrowhead.

TODAY'S FREE FLY STORIES

DOV

Dover

$95.71

-0.24 (-0.25%)

06:50
10/17/19
10/17
06:50
10/17/19
06:50
Earnings
Dover tightens FY19 adj. EPS view to $5.82-$5.85 from $5.75-$5.85 

Consensus $5.82.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 11

    Nov

SON

Sonoco

$58.27

0.75 (1.30%)

06:49
10/17/19
10/17
06:49
10/17/19
06:49
Earnings
Sonoco narrows FY19 base EPS view to $3.50-$3.54 from $3.52-$3.62 »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

DOV

Dover

$95.71

-0.24 (-0.25%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Earnings
Dover reports Q3 adj. EPS $1.60, consensus $1.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 11

    Nov

ARQL

ArQule

$8.97

0.32 (3.70%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Initiation
ArQule initiated  »

ArQule initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Earnings
Breaking Earnings news story on Sonoco »

Sonoco sees Q4 base EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:47
10/17/19
10/17
06:47
10/17/19
06:47
Earnings
Sonoco reports Q3 base EPS 97c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BWXT

BWX Technologies

$56.09

-0.33 (-0.58%)

06:46
10/17/19
10/17
06:46
10/17/19
06:46
Hot Stocks
BWX Technologies awarded $806M contract from U.S. Navy »

BWX Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Recommendations
Netflix analyst commentary  »

SunTrust incrementally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AAPL

Apple

$234.59

-0.67 (-0.28%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Periodicals
EU examining Apple Pay for antitrust concerns, FT reports »

Apple's Apple Pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ALV

Autoliv

$80.64

0.93 (1.17%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Upgrade
Autoliv rating change  »

Autoliv upgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$255.02

-19.58 (-7.13%)

06:44
10/17/19
10/17
06:44
10/17/19
06:44
Recommendations
ServiceNow analyst commentary  »

ServiceNow selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:43
10/17/19
10/17
06:43
10/17/19
06:43
Periodicals
We Company forms committee to consider financing lifeline, Reuters reports »

The We Company (WE) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

JPM

JPMorgan

$119.70

-0.25 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 14

    Jan

CDXC

ChromaDex

$3.41

0.41 (13.67%)

06:41
10/17/19
10/17
06:41
10/17/19
06:41
Hot Stocks
ChromaDex reports new study on nicotinamide riboside importance »

ChromaDex announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BC

Brunswick

$55.47

0.46 (0.84%)

06:39
10/17/19
10/17
06:39
10/17/19
06:39
Downgrade
Brunswick rating change  »

Longbow downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MTB

M&T Bank

$159.14

0.27 (0.17%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Earnings
M&T Bank reports Q3 EPS $3.47, consensus $3.57 »

Reports Q3 common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NEPT

Neptune Wellness

$3.49

0.03 (0.87%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Neptune Wellness to provide extraction services to farming services operation »

Neptune Wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSRGY

Nestle

$0.00

(0.00%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Nestle says portfolio management 'fully on track' »

Nestle notes that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNA

Snap-On

$157.68

-0.64 (-0.40%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Hot Stocks
Snap-On sees 2019 CapEx $95M-$105M »

Sees 2019 effective…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle backs underlying FY19 EPS in constant currency up vs. last year »

Full-year guidance for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle reports nine month sales CHF68.367B vs. CHF66.424B last year »

Organic growth reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$17.70

-0.08 (-0.45%)

06:35
10/17/19
10/17
06:35
10/17/19
06:35
Earnings
KeyCorp reports Q3 ex-items EPS 48c, consensus 46c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HON

Honeywell

$163.86

0.2 (0.12%)

06:35
10/17/19
10/17
06:35
10/17/19
06:35
Earnings
Honeywell narrows FY19 EPS view to $8.10-$8.15 from $7.95-$8.15, consensus $8.09 »

Narrows FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NSRGY

Nestle

$0.00

(0.00%)

06:34
10/17/19
10/17
06:34
10/17/19
06:34
Hot Stocks
Nestle to distribute CHF20B to shareholders via share buybacks »

Nestle's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$3.07

0.335 (12.27%)

, NSRGY

Nestle

$0.00

(0.00%)

06:34
10/17/19
10/17
06:34
10/17/19
06:34
Hot Stocks
New Age Beverages partners with Nestle to relaunch NESTEA in U.S. »

New Age Beverages (NBEV)…

NBEV

New Age Beverages

$3.07

0.335 (12.27%)

NSRGY

Nestle

$0.00

(0.00%)

KO

Coca-Cola

$53.49

-0.02 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSM

TSMC

$50.14

-0.28 (-0.56%)

06:33
10/17/19
10/17
06:33
10/17/19
06:33
Hot Stocks
Breaking Hot Stocks news story on TSMC »

TSMC sees FY19 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.